Ramprasad Dandillaya, MD
Cardiovascular Disease · Las Vegas, NVNPI 1316900236
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.9% of the total across 497 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 60 manufacturers, the largest accounting for just 15.9% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $2,651, 3.6 times the $736 reported in 2019.
Across 497 payments — averaging $23.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$2K
- Amgen$2K
- Bayer$760
- Edwards Lifesciences$749
- E.r. Squibb & Sons, L.L.C.$576
- Boehringer Ingelheim$556
- plus $6K from 54 others
Across 263 payments — averaging $6748.44 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Regeneron$780K
- GSK$584K
- Janssen Research & Development, LLC$124K
- Amgen$105K
- Sanofi$69K
- Novartis$39K
- plus $75K from 6 others
What the payments were for
- Food & beverage$11,790100%
- Education$60%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$11,796 in reported general payments places this provider in the 75th percentile of 165 cardiovascular disease providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 178 | $195,517 |
| Repatha SureclickEvolocumab | 226 | $192,916 |
| EntrestoSacubitril/Valsartan | 55 | $58,456 |
| JanuviaSitagliptin Phosphate | 40 | $50,619 |
| OzempicSemaglutide | 35 | $46,304 |
| XareltoRivaroxaban | 35 | $42,329 |
| MounjaroTirzepatide | 31 | $36,935 |
| JardianceEmpagliflozin | 38 | $36,901 |
| Praluent PenAlirocumab | 47 | $30,361 |
| EdarbiAzilsartan Medoxomil | 26 | $10,791 |
| Ezetimibe | 268 | $9,774 |
| Rosuvastatin Calcium | 382 | $8,140 |
| VascepaIcosapent Ethyl | 22 | $7,540 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 12 | $7,394 |
| ZoloftSertraline Hcl | 13 | $5,528 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $549 | $195,517178 claims |
| NovartisEntresto | $1,881 | $58,45655 claims |
| MerckJanuvia | $70 | $50,61940 claims |
| Novo NordiskOzempic | $392 | $46,30435 claims |
| Johnson & JohnsonXarelto | $366 | $42,32935 claims |
| Boehringer IngelheimJardiance, Pradaxa | $556 | $39,47352 claims |
| Lilly USA, LLCMounjaro | $157 | $36,93531 claims |
| Arbor Pharmaceuticals, Inc.Edarbi, Edarbyclor | $72 | $13,74138 claims |
| GSKTrelegy Ellipta | $76 | $7,39412 claims |
| AbbVieSynthroid | $58 | $5,10263 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 165 cardiovascular disease providers in Nevada.
Other cardiovascular disease in Las Vegas
- Arjun GururajLas Vegas$399K
- Branavan UmakanthanLas Vegas$109K
- Jawad KianiLas Vegas$73K
- Amish PrasadLas Vegas$58K
- Chowdhury AhsanLas Vegas$41K
- Sanjay MalhotraLas Vegas$41K
- William ReshLas Vegas$39K
- Ali NamaziLas Vegas$38K
- Herbert Cordero YordanLas Vegas$38K
- Alfred DanielianLas Vegas$30K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.